Mechanism of Action and Selectivity
Flucytosine is a classic prodrug. To exert its antifungal effect, the molecule must enter the pathogen cell and undergo activation.
Uptake from the extracellular environment is mediated by a specific transport protein, cytosine permease. This step establishes the selectivity of the drug, as mammalian cell membranes lack this specific transporter.
Once inside the fungi, flucytosine is acted upon by the enzyme cytosine deaminase. This reaction produces 5-fluorouracil (5-FU), a potent cellular toxin and antimetabolite widely used in oncology. Human cells lack cytosine deaminase, preventing the direct intracellular formation of 5-fluorouracil within the host organism.
How Does the Fungal Cell Die?
The resulting 5-fluorouracil triggers two parallel pathways of metabolic disruption that ultimately lead to cell division arrest (fungistatic effect).
- Blockade of DNA Synthesis. The metabolite is converted into 5-fluoro-2'-deoxyuridine monophosphate (5-FdUMP) with the participation of ribonucleotide reductase. This compound binds and inhibits the enzyme thymidylate synthase. Without it, the conversion of deoxyuridine monophosphate (dUMP) to deoxythymidylate (dTMP) is impossible, causing an acute pyrimidine deficiency and a complete halt in DNA assembly.
- Synthesis of Defective Proteins. Through the second pathway, 5-fluorouracil is phosphorylated to triphosphate (5-FUTP). This molecule structurally mimics uracil and is erroneously incorporated into the RNA chain. Defective proteins incapable of performing normal functions are then synthesized based on this altered RNA.
Pharmacokinetics and Spectrum of Activity
The drug can be administered both orally and via intravenous infusion. Because of its relatively short half-life, frequent dosing every 6 hours is required.
Flucytosine is characterized by a large volume of distribution and excellent penetration across blood-tissue barriers. It readily crosses the blood-brain barrier: its cerebrospinal fluid level ranges from 65 to 90% of the plasma concentration. It also achieves high concentrations in ocular tissues and the urinary tract.
As monotherapy, the drug is effective against systemic candidiasis, cryptococcosis, and chromoblastomycosis.
Why Combine with Amphotericin B?
In clinical practice, flucytosine is rarely used alone and is most commonly combined with amphotericin B. This represents a classic example of pharmacological synergism.
Amphotericin B damages the fungal plasma membrane. Through the resulting membrane pores, flucytosine enters the cell much more easily and in larger quantities.
This combination offers several key advantages:
- It allows a reduction in the dosage of toxic amphotericin B.
- It shortens the overall duration of therapy.
- It prevents the rapid development of resistance, which is otherwise inevitable with flucytosine monotherapy.
This combination is actively used to treat severe infections: cryptococcal meningoencephalitis and endocarditis, as well as aspergillosis and candidiasis involving the central nervous system and urinary tract.
Adverse Effects and the Toxicity Paradox
Although human cells cannot convert flucytosine into toxic 5-fluorouracil, the drug still causes adverse effects typical of cytostatics.
The reason lies in the intestinal microflora. Bacteria and fungi residing in the gastrointestinal tract possess the necessary enzymes, metabolizing a portion of the drug into 5-fluorouracil, which is subsequently absorbed into the systemic circulation and exerts host toxicity.
Major adverse reactions include:
- Hematologic: bone marrow suppression (leukopenia, thrombocytopenia).
- Gastrointestinal: dyspeptic symptoms (nausea, vomiting, diarrhea).
- Hepatobiliary: liver function abnormalities.
- Dermatologic: skin rashes.
The drug has an absolute contraindication and must never be used during pregnancy.